Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL - Contacts and Locations

Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL

This study is ongoing, but not recruiting participants.
Information provided by Weill Medical College of Cornell University

Please refer to this study by its ClinicalTrials.gov identifier: NCT00151320

Locations


United States, Massachusetts
	Dana Farber Cancer Institute
	Boston, Massachusetts, United States, 02115

United States, Nebraska
	Nebraska Medical Center
	Omaha, Nebraska, United States, 68198

United States, New York
	Weill Medical College of Cornell University
	New York, New York, United States, 10021
	Columbia University College of Physicians and Surgeons
	New York, New York, United States, 10032

Sponsors and Collaborators

Weill Medical College of Cornell University

Millennium Pharmaceuticals

Investigators


Principal Investigator:	John P Leonard, MD	Weill Medical College of Cornell University